News just out:
IMMP is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two stage clinical trial design. Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients, forming Stage 2 of Part B. The decision follows a preliminary safety and efficacy review by the Data Monitoring Committee and its recommendation, based on the patients recruited in Stage 1 of Part B
News just out: IMMP is pleased to report it has decided to...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.010(3.17%) |
Mkt cap ! $454.5M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.5¢ | $550.2K | 1.769M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 298345 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 213308 | 21 |
View Market Depth
| Last trade - 13.44pm 16/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |